AB Science reports interim financial results and updates development strategy
Paris-based AB Science has released its financial results for the first half of 2026 while adjusting its operational roadmap following a regulatory clinical practice inspection.
AB Science has published its financial results for the six-month period ending June 30, 2026. The company concurrently announced a revision of its operational plan and financial calendar, citing the impact of a recent inspection regarding Good Clinical Practice (GCP) standards.
In late September, the company noted that the regulatory inspection necessitated structural changes to its research and development operations. These adjustments are intended to align ongoing clinical projects with necessary compliance protocols, leading to a recalibration of the company's long-term development milestones.
Prior to the report, AB Science completed a private placement in August 2026, raising 14.2 million euros to support its capital structure. The company continues to provide regular updates to investors via web conferences to explain the current operational shifts.